Neko Health

Neko Health is a Swedish healthtech company founded in 2018 by Daniel Ek and Hjalmar Nilsonne to shift healthcare from reactive treatment towards prevention. Its main product, the Neko Health Scan, combines in-house sensors and medical devices, blood analysis, skin mapping, cardiovascular measurements and an in-person physician review. The radiation-free experience takes about one hour and delivers results during the same appointment. Neko's advantage does not come from a single test. It comes from vertically integrating hardware, software, clinical protocols, physical clinics, physicians, an app and longitudinal data. The first scan creates a baseline, while later visits reveal how skin marks, blood pressure, cholesterol, blood sugar and other indicators change over time. This continuity increases customer value and may create a data and operational-learning moat. Commercial demand is already strong. The company reports more than 100,000 completed scans in Sweden and the UK, over 350,000 people registered or waiting, and a 75% rate of members booking and prepaying for the following year's scan at the end of their first appointment. In July 2026 Neko raised a $700 million Series C led by Lightspeed Venture Partners and co-led by O.G. Venture Partners. The Financial Times reported a valuation close to $7 billion. The capital will fund its US entry, beginning in New York, as well as further investment in research, technology and clinical capacity. The long-term clinical case remains unproven. Observational data published by the company shows that it can identify important conditions and that some returning members improved selected health markers, but the evidence does not come from controlled trials. Screening asymptomatic people also carries risks including false positives, overdiagnosis, anxiety and unnecessary follow-up. Neko must therefore prove both that its physical clinic network can scale and that its model improves long-term health outcomes.